[ A21-23] Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Last updated 19.08.2021

Project no.:
A21-23

Commission:
Commission awarded on 18.02.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy

Result of dossier assessment:

Indication of minor added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2021-08-19 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.